PropertyValue
?:abstract
  • Johnson & Johnson has hired Emergent BioSolutions as a US manufacturing partner for its lead COVID-19 vaccine candidate Under the pact, worth about $135 million, Emergent will make the vaccine’s active ingredient starting later this year at its facility in Baltimore J&J also signed a deal to use capacity at Catalent’s biologic drug facility in Bloomington, Indiana J&J has a plan to produce 1 billion doses of its adenovirus-based vaccine View: PDF ;Full Text HTML
?:creator
?:journal
  • C&EN_Global_Enterprise
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • J&J picks partners for COVID-19 vaccine
?:type
?:who_covidence_id
  • #164924
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/c9rgi3zn>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/c9rgi3zn>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all